Authors
Latest:
Massimo Trucco, MD, on the Potential of Islet Cell TransplantThe director of the Alleghany Health Network Institute of Cellular Therapeutics discussed possible applications of the procedure.
Latest:
Omid Hamid, MD, on Post-Approval Research With LifileucelThe professor from Cedars Sinai discussed data he is anticipating from further investigations into lifileucel.
Latest:
Encapsulated Cell Therapy for Retinal DiseasesJohn Pollack, MD, discusses gene therapy advancements for retinal diseases.
Latest:
Shebli Atrash, MD, on BCMA-Directed Therapy Options for Multiple MyelomaShebli Atrash, MD, discussed the current landscape of available BCMA-directed therapies for treating multiple myeloma.
Latest:
CARTITUDE Trials in Multiple MyelomaExperts discussed safety and efficacy data of cilta-cel for R/R MM from the CARTITUDE-1 and CARTITUDE-2 studies.
Latest:
Future Research in Gene and Cell Therapy ConditioningKevin Heller, MD, executive vice president of research, Jasper Therapeutics, discussed future research with JSP191.
Latest:
Advantages of Concurrently Investigating Gene Therapies in Dogs and HumansDan Oliver, cofounder and chief executive officer, Rejuvenate Bio, discussed the advantages of developing gene therapies for both dogs and humans.
Latest:
Sid Kerkar, MD, on Developing CAR T Therapies Without Lymphodepletion ChemotherapyThe vice president of oncology and research and development at Exuma Biotech discussed the company’s platforms, including CAR-TaNK cells.
Latest:
Matthew Frigault, MD, MS, on CART-ddBCMA's Potential in Multiple MyelomaThe study's primary investigator shared his thoughts on where CART-ddBCMA could fit within the treatment landscape.
Latest:
Axi-Cel vs Tisa-Cel in R/R Diffuse Large B-Cell Lymphoma : Guenther Koehne, MD, PhDThe deputy director and chief of stem cell transplantation at Miami Cancer Institute discussed the study of axicabtagene ciloleucel vs tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma.
Latest:
Jonathan Yen, PhD, on Continuing Research With Prime Editing for Sickle Cell DiseaseThe director of therapeutic genome engineering, St. Jude Children’s Research Hospital discussed challenges with performing prime editing in cells.
Latest:
Multiple Myeloma KarMMA Trial Methodology: Larry Anderson, MDThe associate professor from Harold C. Simmons Comprehensive Cancer Center discussed the methodology of the phase 2 KarMMa trial.
Latest:
Bringing Gene Therapies to Market With the Help of MEAsWith a new paradigm of treating previously incurable diseases comes a new pay paradigm for million-dollar therapies.
Latest:
Developing a Safer Allogeneic Cell Therapy for Ovarian CancerMichael Heffernan, chairman and chief executive officer, Avenge Bio, discussed AVB-001's lower systemic toxicity profile seen in preclinical studies.
Latest:
Ben Creelan, MD, on the Potential of Logic-gated Tmod CAR-T in Lung Cancer and Other Solid TumorsThe medical oncologist at Moffitt Cancer Center spoke about A2 Bio’s A2B530 as part of a larger discussion of novel cell therapy approaches in solid tumors.
Latest:
Evan Zynda, PhD, on Optimizing Manufacturing to Increase Access to Cell TherapyThe senior scientist at Thermo Fisher Scientific discussed the company’s approach to scaling and strategic partnerships.
Latest:
Claire Roddie PhD, FRCPath, MBChB, MRCP, on the Potential Advantage Obe-cel's Fast Off-rate CD19 Binding DomainThe associate professor at University College London also discussed unmet needs that remain in r/r B-ALL and another presentation of interest at ASCO’s 2023 conference.
Latest:
Rajni Agarwal-Hashmi, MD, on Safety Advantages of Gene Therapy in Fanconi Anemia Over SOCThe professor of pediatrics at Stanford Cancer Institute discussed recent data from clinical trials of the lentiviral gene therapy RP-L102.
Latest:
CAR T and Other Emerging Therapies in R/R Multiple Myeloma: Kenneth H. Shain, MD, PhDThe hematologist/oncologist at Moffitt Cancer Center discussed emerging therapies for patients with relapsed/refractory multiple myeloma.
Latest:
Paula Rodríguez Otero, MD, PhD, on Demonstrating Ide-cel's PFS Superiority in Triple-Class-Exposed R/R Multiple MyelomaThe hematologist at the University of Navarra discussed updated data from the phase KarMMa-3 trial.
Latest:
J. Andrew Livingston, MD, on Starting the Shift Toward Targeted Therapies in SarcomaThe associate professor at MD Anderson Cancer Center discussed his future outlook and goals for the field of sarcoma.
Latest:
Dan Shelly, PhD, on Developing an Allogeneic, Adaptable CAR PlatformThe vice president of business development and alliances at Prescient Therapeutics discussed advantages of the OmniCAR, SpyTag, and SpyCatcher technologies.
Latest:
Targeting Cancers With CAR T and NK CellsJan Davidson, MD, PhD, chief medical officer, Wugen, discussed the company’s future plans and research.
Latest:
The Potential of ALLO-715 in Relapsed/Refractory Multiple Myeloma: Doris Hansen, MDThe hematologist from Moffitt Cancer Center discussed the promise of ALLO-715 in relapsed/refractory multiple myeloma.
Latest:
Gene Therapy Well-Tolerated in Late-Onset Pompe DiseaseInterim safety data from the FORTIS study were presented at WORLDSympsoium.
Latest:
Exploring Advanced Approaches for Pain ReliefThe chief executive officer and co-founder of Flexion Therapeutics discussed the company’s pain-focused pipeline, which includes a gene therapy that targets inflammation.
Latest:
Thomas Povsic, MD, PhD, on Ongoing Research With XC001 Angina Gene TherapyThe interventional cardiologist and professor, Duke University School of Medicine, discussed other populations that may benefit from XC001 and the challenges and opportunities with a surgical delivery of treatment.
Latest:
1-Year Data on Omidubicel Shows Sustained Benefits, Reduced Infection RatesThere was a continued trend toward improvement of overall survival with omidubicel at 73% compared with UCBT at 60%.
Latest:
The Growing Popularity of Gene Therapy for Retinal DiseasesFoundation Fighting Blindness is helping to support the development of gene therapies for retinal diseases.
Latest:
Advantages of CG0070 Over Standard Care for Non-Muscle Invasive Bladder CancerThe chief executive officer of CG Oncology discussed the role of CG0070 in patients who are unresponsive and responsive to Bacillus Calmette-Guerin immunotherapy.
